The Fuxing Program was established in Zhuhai as an action plan to micro-eliminate hepatitis C in response to the World Health Organization's goal of eliminating hepatitis C by 2030. Therefore, the effectiveness of this program in terms of hepatitis C screening, treatment, follow-up, and other aspects is evaluated here. The "Fuxing Project" was established in May 2021 under the supervision of the Zhuhai Medical Quality Control Center for Infectious Diseases. A bridge was formed among the governmental entities, hospitals at all levels, and the community to train hepatitis C prevention and control strategies. Hepatitis C screening, publicity, and educational awareness were conducted in-and out-of-hospital. The responsibility for the diagnosis, treatment, and follow-up of a patient with hepatitis C was assigned to the staff. The screening and treatment rates of hepatitis C in hospitals before and after the initiation of the project were compared and analyzed using the test or Fisher's exact test. The hepatitis C virus (HCV) infection and treatment status were investigated and analyzed among the general population, high-risk populations such as human immunodeficiency virus (HIV) infection, drug addicts, and the population residing in supervised sites within Zhuhai communities, rural areas, schools, or factories. Anti-HCV positivity rate (0.82% vs. 0.43%, <0.001), HCV RNA detection rate (98.1% vs. 59.5%, <0.001), HCV RNA detection positivity rate (52.56% vs. 29.76%, <0.001), HCV RNA positivity rate (0.4% vs. 0.13%, <0.001), and hepatitis C treatment rate (76.76% vs. 31.97%, <0.001) were significantly higher among the inpatient population after the Fuxing Program initiation than before. The HCV RNA detection rate (58.52% vs. 6.93%, <0.001) and HCV RNA detection positivity rate (77.72% vs. 29.41%, <0.001) in Zhuhai were significantly higher after the Fuxing Program initiation than before. Anti-HCV positivity rate (0.46% vs. 1.28%, =0.009) and HCV RNA (0.32% vs. 0.99%, =0.03) were significantly lower in the Zhuhai general population of urban communities than those of the general population in rural areas. The HCV infection rate was more than three times higher in rural populations than in urban populations. Anti-HCV positivity rate, HCV RNA positivity rate, HCV RNA detection positivity rate, and hepatitis C treatment rates were 2.64% (31/1 175), 3.40% (69/2 022) and 94.4% (34/36), 2.64% (31/1 175), 2.72% (55/2 022), 50.00% (18/36), and 100% (31/31), 79.71% (55/69) and 52.94% (18/34), and 100% (31/31), 0 (0/55) and 55.55% (10/18) among the HIV infection, supervised population under supervised sites, and methadone maintenance treatment clinic population, respectively. Anti-HCV positivity rate (4.15% vs. 0.72%, <0.001) and HCV RNA (3.22% vs. 0.53%, <0.001) were significantly higher in the high-risk group than those in the general population, while the treatment rate of hepatitis C in the high-risk group (39.42% vs. 82.35%, <0.01) was significantly lower than that of the general population. The establishment of the hospital grid linkage mechanism and the management model of hepatitis C follow-up by specialists, with the infectious diseases medical quality control center as the supervisory body, have improved the screening rate, the HCV RNA detection rate, and the treatment rate in the hospital, thereby providing a reference for exploring a management model to eliminate the nationwide threat of hepatitis C.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3760/cma.j.cn501113-20240224-00091 | DOI Listing |
Int J STD AIDS
March 2025
MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.
BackgroundHepatitis B virus (HBV) disproportionately affects people at risk of HIV. Encounters for HIV post-exposure prophylaxis (PEP) create opportunities for HBV screening and prevention. We quantified HBV prevalence, susceptibility, and active/passive immunization use among patients seeking HIV PEP.
View Article and Find Full Text PDFAliment Pharmacol Ther
March 2025
Sialkot Medical College, Sialkot, Punjab, Pakistan.
Cells
February 2025
Fiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.
Several immunoregulatory or immune checkpoint receptors including T cell immunoglobulin and mucin domain 3 (TIM-3) have been implicated in glioblastoma progression. Rigorous investigation over the last decade has elucidated TIM-3 as a key player in inhibiting immune cell activation and several key associated molecules have been identified both upstream and downstream that mediate immune cell dysfunction mechanistically. However, despite several reviews being published on other immune checkpoint molecules such as PD-1 and CTLA-4 in the glioblastoma setting, no such extensive review exists that specifically focuses on the role of TIM-3 in glioblastoma progression and immunosuppression.
View Article and Find Full Text PDFRheumatology (Oxford)
March 2025
Norwich Medical School, University of East Anglia, Norwich, UK.
Polyarteritis nodosa (PAN) was first described in 1852 with the first widely recognised description in 1866 by Kussmaul and Meier. Since then our concepts of the condition have evolved, with recognition of the difference between polyarteritis nodosa and microscopic polyangiitis (MPA). Classification criteria for PAN remain unsatisfactory.
View Article and Find Full Text PDFRheumatology (Oxford)
March 2025
Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Altindag, Ankara, Türkiye.
Polyarteritis Nodosa (PAN), is the firstly described vasculitis and can be seen in paediatric and adult age. PAN has a heterozygous clinical picture including cutaneous, constitutional, musculoskeletal, gastrointestinal, and renal involvement. Description and splitting of other vasculitis, makes this medium vessel vasculitis, a very rare disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!